Enanta Pharmaceuticals Inc (ENTA)

Enanta Pharmaceuticals Inc (ENTA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $352M; returns 1 day +0.2%, 1 week +4.9%, 1 year +9.1%.

Enanta Pharmaceuticals Inc. is a clinical-stage biotechnology company primarily focused on the discovery and development of small molecule drugs for viral infections and immunological diseases. The company's revenue is predominantly generated from royalty payments derived from worldwide net sales of AbbVie's hepatitis C virus (HCV) regimen, MAVYRET®/MAVIRET®.

Groups ENTA belongs to

• Biotechnology
• Clinical Stage
• Clinical Stage Biotech
• Healthcare
• Royalty Streams
• Infectious Diseases
• Drug Discovery
• Antivirals
• Life Sciences
• Fast Track Designation
• Autoimmune Diseases

ENTA financial model: income statement, cash flow and balance sheet